– CANADA, Toronto – Antibe Therapeutics Inc (TSX: ATE | OTC: ATBPF), a clinical-stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced the appointment of Robert Hoffman and Jennifer McNealey to its Board of Directors.
“We are delighted to welcome Jennifer and Robert to our team,” said Board Chair, Walt Macnee. “Both are highly accomplished biotechnology executives, with significant experience in U.S. capital markets, public company governance and financial operations – all of which will be invaluable to Antibe as we move toward a potential listing on a senior U.S. exchange in parallel with large market partnering efforts.”
About Robert Hoffman
Until his retirement last month, Mr. Hoffman was CFO of San Diego-based Heron Pharmaceuticals, a NASDAQ-listed commercial-stage drug developer with a pipeline of acute pain therapeutics. During his tenure at Heron, the company raised more than $650 million and launched its second commercial drug product. His career in the sector began in 1997 at Arena Pharmaceuticals, where he rose to become CFO, holding that position for ten years. While at Arena, he was involved with its IPO and financings raising more than $1.5 billion.
Mr. Hoffman is currently a member of the boards of three NASDAQ-listed pharmaceutical companies: Kura Oncology, Kintara Therapeutics (as Chairman), and ASLAN Pharmaceuticals; he previously served as a board member for three other publicly listed biotechnology companies. Trained as a Certified Public Accountant, he is a longstanding member of the Small Business Advisory Committee of the Financial Accounting Standards Board. Mr. Hoffman is also a founding board member of Day for Change, which has funded charities serving underprivileged and abused children in the San Diego area for 20 years.
Mr. Hoffman commented, “I’m excited to join Antibe’s board. The market opportunity for safer, non-opioid pain therapeutics has never been greater. And with otenaproxesul moving into its Phase III program, the company’s strategic opportunities are also expanding. It’s a great time to work with Antibe’s impressive team to capture the full potential of a uniquely promising drug pipeline and platform.”
About Jennifer McNealey
Ms. McNealey is a senior financial and strategy executive with a considerable breadth of experience in the biotechnology sector, as an analyst, portfolio manager, information provider, and expert in corporate communications and investor relations. She is currently VP, Investor Relations and Strategy for South San Francisco-based Calithera Biosciences, a clinical-stage developer of small-molecule oral therapies targeting a range of cancers and other life-threatening diseases. Ms. McNealey began her career as a healthcare equity analyst, transitioning to the management of biopharmaceutical-focused investment funds for Morgan Stanley Dean Witter Advisors, Amerindo Investment Advisors, and latterly at Franklin Templeton, where she co-managed the Franklin Biotechnology Discovery Fund. She subsequently founded Laurient LLC, independent equity research and competitive intelligence platform analyzing publicly-traded biopharmaceutical companies.
Since 2013, Ms. McNealey has served on the board of Enzon Pharmaceuticals. She earned her B.A. and Master of Health Administration degrees from Cornell University.
Ms. McNealey said, “The severe shortcomings of today’s pain medications constitute one of the world’s most pressing medical needs. Patients deserve better. Antibe’s novel drug platform is a promising way forward – I am delighted to be a part of it.”
About Antibe Therapeutics Inc.
Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation, safer nonsteroidal anti-inflammatory drugs for pain and inflammation arising from a wide range of medical conditions. Antibe is developing three assets that seek to overcome the gastrointestinal ulcers and bleeding associated with NSAIDs. Antibe’s lead drug, otenaproxesul (ATB-346), is entering Phase III for osteoarthritis pain. Additional assets under development include a safer alternative to opioids for perioperative pain and a GI-safe alternative to low-dose aspirin.
For more information: https://antibethera.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
